Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Index Ventures
BioCentury | Jul 27, 2023
Finance
Medicxi stays the course with ‘classically’ sized $400M fourth fund
With recent exits and an optimistic eye toward market improvements, Francesco De Rubertis discusses how the European VC is investing new fund
BioCentury | Jul 14, 2023
Finance
July 13 Quick Takes: Apogee prices $300M IPO
Plus: New funds for BGV, Modi; Arix reviewing alternatives; and updates from Bicycle, Roche, Causaly, Neuren-Acadia
BioCentury | Dec 6, 2022
Finance
Avalon creates pure-play biotech VC with new $135M fund
After 11 funds that balanced tech and life sciences, the new Avalon BioVentures will preserve the firm’s sweat equity model
BioCentury | Jul 16, 2022
Finance
New parallel fund offers Qiming LPs more healthcare exposure
Chinese VC’s newest offering among three new funds totaling $3.2B
BioCentury | Jul 1, 2022
Finance
After Forty Seven takeout, MacQuitty finding ‘freedom’ with Lightspeed team
Hybrid firm’s ‘leap’ backing Stanford spinout spurred more life sciences deals, with onetime Abingworth partner building team and portfolio
BioCentury | Sep 22, 2020
Finance
Medicxi adds firepower for maturing portfolio via first secondary fund
Strategic growth vehicle will support companies backed by Index still advancing toward value-creating points.
BioCentury | Nov 15, 2019
Product Development
Minerva on the verge in neuropsychiatry with two compounds close to verdict
Minerva nears make-or-break readouts from its two founding neuropsychiatry programs
BioCentury | Jul 18, 2019
Financial News
Medicxi’s new €400M fund unites early, late stage investing
In age of megarounds, Medicxi is sticking with its asset-focused approach with its third fund
BioCentury | May 28, 2019
Finance
NanoDimension adding European focus for new $335M fund
With third fund, NanoDimension planning its first-ever European investments while doubling down on therapeutics
Items per page:
1 - 10 of 224